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O
ver the past two decades there have been signiﬁ  cant 
achievements in the control of a handful of 
important human tropical infections [1]. These 
achievements include the substantive reductions in the 
prevalence and incidence of the so-called neglected diseases 
such as lymphatic ﬁ  lariasis, onchocerciasis, guinea worm, 
leprosy, and trachoma (Box 1) [2]. 
Each of these neglected diseases is a poverty-promoting 
and often stigmatizing condition occurring primarily in 
rural areas of low-income countries (Box 2) [3]. They are 
ancient afﬂ  ictions, described in the Bible and other ancient 
texts, which have burdened humanity for millennia [3]. But 
now, as a result of aggressive regional vertical interventions, 
there is a possibility that some neglected tropical infections 
could be eventually controlled to the point of elimination in 
some areas of endemicity [2–8]. In the case of guinea worm 
infection, disease eradication might also soon be possible [9]. 
Neglected by Policy Makers and Donors
Somewhat surprisingly, policy makers and public health 
ofﬁ  cials have largely ignored the extraordinary successes 
in these vertical programmes for neglected disease control 
and elimination. We believe that there are two main reasons 
for this lack of attention. The ﬁ  rst is that the international 
health community, including donors, have given the highest 
priority to the “big three”—HIV/AIDS, tuberculosis (TB), 
and malaria—with the result that other infections of poverty 
garner less attention. The second is that donors and policy 
makers take a dim view of the overall value of vertical 
programmes that are not directed at the big three. 
With regards to the big three, donors, international 
agencies, nongovernmental development agencies, and 
governments have responded through focused attention on 
vertical initiatives by creating UNAIDS (http:⁄⁄www.unaids.
org) and within WHO, Stop TB (http:⁄⁄www.stoptb.org) 
and Roll Back Malaria (http:⁄⁄www.rollbackmalaria.org). 
These developments stimulated the establishment of the 
Global Fund to Fight AIDS, TB and Malaria (http:⁄⁄www.
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Box 1. The Thirteen Neglected Tropical Diseases 
in Africa and Their Major Etiologic Agents 
Protozoan Infections
African trypanosomiasis  Trypanosoma gambiense, 
T. rhodesiense
Kala-azar (visceral leishmaniasis)  Leishmania donovani
Helminth Infections
STH Infections
Ascariasis  Ascaris lumbricoides
Trichuriasis  Trichuris trichiura
Hookworm infection  Necator americanus
Schistosomiasis
Urinary schistosomiasis  Schistosoma haematobium
Hepatobiliary schistosomiasis  Schistosoma mansoni
Lymphatic ﬁ  lariasis  Wuchereria bancrofti
Onchocerciasis  Onchocerca volvulus
Dracunculiasis  Dracunculus medinensis
Bacterial Infections
Trachoma  Chlamydia trachomitis
Leprosy  Mycobacterium leprae
Buruli ulcer  Mycobacterium ulcerans
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theglobalfund.org), a ﬁ  nancing mechanism that provides 
up to ﬁ  ve years of funding to projects relating to these three 
diseases. 
However, this ﬁ  nancing mechanism contrasts with the 
approach to ﬁ  nancing health in many developing countries 
that is preferred by many bilateral donors, called sector-
wide approaches. In a sector-wide approach, donors agree 
to contribute to a single basket of funds, which in turn 
contributes to the developing country’s national plan [10,11]. 
There has been recognition that many of the speciﬁ  c problems 
of health cannot be resolved without effective health systems. 
Following the World Development Report of 1993, the World 
Bank promoted the concept of the need for a minimum health 
package that both governments and donors could afford 
[12]. In recent times, a large number of policy papers on 
strengthening health systems have appeared, many of which 
were presented at the Ministerial Summit in Mexico [13]. 
The Ministerial Summit made speciﬁ  c recommendations, 
particularly in the areas of health systems research; the 
mantra was that strengthening health systems is a prerequisite 
for improving health, and more health systems research is 
required to ensure cost-effectiveness of investment [13].
Neglected Diseases and the Millennium 
Development Goals
At the same time, there has also been increased attention 
on the relationship between health and poverty, especially 
in relation to the Millennium Development Goals (MDGs). 
These goals, endorsed by the international community, 
include the goal of reducing the number of people living 
in absolute poverty by 50% by 2015 (http:⁄⁄www.un.org/
millenniumgoals). A review of the progress toward these 
goals—the UN Millennium Project—has recently been 
published, which identiﬁ  ed sub-Saharan Africa as signiﬁ  cantly 
lagging in meeting MDGs compared to other regions [14]. 
Several of these goals have speciﬁ  c health-related targets, 
but only the big three feature within the MDGs themselves. 
Other infections, including the neglected tropical diseases, 
which affect at least as many poor people as the big three, are 
relegated dismissively to the category of “other diseases.” 
In parallel with changes in health ﬁ  nancing and policy 
and the growing awareness of the need to strengthen health 
systems, there has been an explosion in the number of 
public–private partnerships (PPPs) created to address speciﬁ  c 
health problems. At the time this article went to press, the 
Initiative on Public Private Partnerships for Health listed 92 
such partnerships in its “partnerships database” (http:⁄⁄www.
ippph.org/index.cfm?page=/ippph/partnerships); several 
of these address parasitic diseases and are based on product 
donations [15,16].
The Commission for Africa (http:⁄⁄www.
commisionforafrica.org), established by the British Prime 
Minister and the Chancellor of the Exchequer, proposes a 
Marshall plan for Africa [17]. Although the commission’s 
report remains focused on HIV/AIDS, TB, and malaria, the 
neglected tropical diseases are also recognized as contributing 
signiﬁ  cantly to the overall African disease burden.
The Burden of Neglected Diseases
In aggregate, the neglected tropical diseases are responsible 
for about 500,000 deaths annually. Using the disability-
adjusted life year as a metric, the burden of neglected tropical 
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Figure 1. Geographic Overlap of the Neglected Tropical Diseases 
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diseases is equivalent to approximately one quarter of the 
disease burden from HIV/AIDS and one half that of malaria 
[3]. However, newer information indicates that even these 
high disability–adjusted-life-year ﬁ  gures grossly underestimate 
the disease burden of neglected tropical diseases [18–20].
Of the listed major neglected diseases, ten of them 
stand out for their high prevalence and intensity in Africa: 
urinary and intestinal schistosomiasis, lymphatic ﬁ  lariasis, 
onchocerciasis, the soil-transmitted helminth (STH) 
infections (ascariasis, trichuriasis, and hookworm infection), 
African trypanosomiasis, kala-azar, Buruli ulcer, and blinding 
trachoma. Up to 90% or more of the world’s disease burden 
from these conditions is believed to occur in Africa (Table 1). 
Evidence for the Value of Integrated Control
Of equal interest is the observation that there are currently 
six major PPPs working in Africa that are engaged in a 
vertical elimination or control programme linked to a 
speciﬁ  c neglected tropical disease (Table 2). In Africa, the 
six PPPs operate in parallel, using control tools comprised 
predominantly of one or two drugs deployed over wide 
areas and among large populations. In aggregate, the six 
PPPs are deploying four drugs—albendazole, ivermectin 
(Mectizan), praziquantel, and azithromycin (Zithromax) —in 
order to target more than 100 million Africans in around 30 
countries. An added beneﬁ  t of the PPP activities is their role 
in strengthening health systems. For example, the African 
Programme for Onchocerciasis Control has established a 
successful community-directed treatment initiative, which has 
provided a valuable entry point for other community-directed 
health interventions in regions where there is little access to 
traditional health services [21].
Closer analysis of the major endemic neglected tropical 
diseases in Africa reveals that they exhibit considerable 
geographical overlap, and hence in many cases are syndemic 
(Figure 1) [22]. Therefore, we believe that there could 
be great value in exploring whether a drug employed by a 
vertical programme that targets one condition could also 
be used to simultaneously make an impact on some of the 
others [23]. For example, because a signiﬁ  cant proportion 
of impoverished school-age children living in Africa carry 
multiple parasitic infections—i.e., they are polyparasitized—
with three different STHs (Ascaris, Trichuris, and hookworm) 
and schistosomes, they could be simultaneously treated with 
two drugs, albendazole and praziquantel [18]. Indeed, in 
2001, the 54th World Health Assembly urged its member 
states to undertake frequent and periodic deworming 
with praziquantel together with either albendazole or 
mebendazole as a means to control and reduce the 
morbidity in this paediatric age group (http:⁄⁄www.who.int/
wormcontrol) [18].
Accordingly, the Schistosomiasis Control Initiative, a 
PPP based in London but working in Uganda, Tanzania, 
Zambia, Mali, Niger, and Burkina Faso, adds albendazole 
to its praziquantel regimen (http:⁄⁄www.schisto.org). 
Similarly, the major drugs used for lymphatic ﬁ  lariasis 
and onchocerciasis control, ivermectin and albendazole 
(http:⁄⁄www.ﬁ  lariasis.org), also target the STHs in 
polyparasitized children as well as adults. Albendazole is the 
drug of choice for most of the STHs, while ivermectin also 
has a signiﬁ  cant anthelmintic effect on Ascaris and Trichuris 
infections, and is the drug of choice for the treatment of 
human strongyloidiasis (http:⁄⁄www.themedicalletter.com/
freedocs/parasitic.pdf). 
More recently, selective mass treatment with ivermectin 
has been shown to also reduce the prevalence of ectoparasitic 
skin infections such as pediculosis, scabies, and tungiasis 
[24] as well as cutaneous larva migrans. Scabies control 
with ivermectin also reduces the occurrence of secondary 
streptococcal skin infections and even renal disease resulting 
from post-streptococcal glomerulonephritis [25]. There is 
also recent evidence that doxycycline and other antibiotics are 
effective in killing the adult ﬁ  larial worm, Wuchereria bancrofti, 
because the ﬁ  larial parasite depends on endosymbiotic 
Wolbachia rickettsia for survival and reproduction [26]. 
Azithromycin, which is used for the control of trachoma 
(http:⁄⁄www.trachoma.org), has also been shown to exhibit 
similar anti-ﬁ  larial activity in vitro [27], although it is not yet 
clear whether this will translate into a public health impact 
on ﬁ  laria. Widespread use of azithromycin could impact on 
other paediatric bacterial infections, including those caused by 
group A streptococci [28].
The Cost-Effectiveness of Integrated Control
Indeed, armed with four drugs (albendazole, ivermectin, 
azithromycin, and praziquantel), the six PPPs could integrate 
control of seven major neglected tropical diseases in Africa. 
In so doing, a rapid impact on morbidity, blindness, and skin 
disease could be achieved at the minimal cost of about US$0.40 
per person per year [23]. For just US$200 million per year 
for ﬁ  ve years, it is estimated that over 500 million individuals 
could beneﬁ  t from preventative chemotherapy, which would 
rapidly contribute to poverty reduction and take steps toward 
seven of the eight MDGs [23]. Poverty reduction would be even 
more likely if the resources were allocated as a package for the 
control or elimination of these diseases of poverty. 
In addition, the calculated economic rates of return 
suggest that investment in control/elimination of these 
diseases produces an economic rate of return of 15%–30%, 
and are capable of delivery on a large scale [1]. The recent 
publication from the Millennium Project lists under its “quick 
wins” (referring to situations in which simple interventions 
could make profound differences to survival and quality of 
life) regular deworming of school-aged children [14], an 
approach strongly advocated in a recent Lancet editorial, 
“Thinking beyond Deworming” [29]. 
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Table 1. Sub-Saharan Africa Has the Highest Prevalence of Nine 
Neglected Tropical Diseases
Condition Cases in Africa Proportion of 
Global Burden 
in Africa
Source
Hookworm infection 198 million 27%–34% [54]
Ascariasis 173 million 14%–22% [54]
Schistosomiasis 166 million 89% [55]
Trichuriasis 162 million 20%–26% [54]
Trachoma 33 million 40% [56]
Lymphatic ﬁ  lariasis 46 million 38%a [57]
Onchocerciasis 18 million 99% [21]
African trypanosomiasis 0.5 million 100% [58]
Dracunculiasis <0.1 million ~100% [59]
aEstimates from proportion of African share of global burden of lymphatic ﬁ  lariasis.
DOI: 10.1371/journal.pmed.0020336.t001PLoS Medicine  |  www.plosmedicine.org 1067
The potential synergies in collateral beneﬁ  ts delivered 
using the four drugs mentioned above is appropriate, as they 
often have compatible approaches to delivery. Furthermore, 
three of these drugs are being donated by multinational 
pharmaceutical companies (ivermectin [Mectizan] by 
Merck & Co., Inc.; azithromycin [Zithromax] by Pﬁ  zer; and 
albendazole by GlaxoSmithKline), two of these—ivermectin 
and albendazole—for “as long as needed” to achieve public 
health goals [21]. 
Praziquantel for schistosomiasis is now signiﬁ  cantly less 
expensive than a decade ago (US$0.07 per tablet, or US$.20 
to treat a child) and so treatment to alleviate morbidity 
from schistosomiasis in some 166 million individuals 
in Africa of all ages and both sexes is now possible 
(http:⁄⁄www.schisto.org). The report of the Commission for 
Africa contains two statements relevant to this possibility: 
“donors should ensure that there is adequate funding for 
the treatment and prevention of parasitic diseases and 
micronutrient deﬁ  ciency;” and “governments and global 
health partnerships should ensure that this [funding] is 
integrated into public health campaigns by 2006” (pp. 72 
and 198 of [30]).
Table 3 presents the numbers requiring treatment for 
each of these infections, the unit drug price (if applicable), 
and the estimated total delivery costs of treating these 
chronic disabling conditions in sub-Saharan Africa. Such 
interventions, which are aggressively pro-poor, are based 
on safe, efﬁ  cacious drugs that reach a high coverage of the 
target population, are known to be cost effective, and do 
not, as yet, have any associated drug resistance. They can be 
delivered through community-directed approaches, school 
health programmes, the World Food Programme school 
feeding programme, or the supplementary feeding and 
nutrition programmes of nongovernmental development 
organizations, usually on an annual basis (http:⁄⁄www.
wfp.org). The estimate of US$.40 per treatment annually 
is equivalent to the bulk cost of about 12 condoms for 
prevention of HIV transmission or a quarter of the price of a 
single antimalarial bednet. 
Scaling Up Integrated Control
A number of issues need to be addressed before integrated 
control of neglected tropical diseases may be practiced on a 
large-scale basis in Africa. For example, the ﬁ  nal costs of an 
integrated package may need to include the costs of drug 
use monitoring and of developing new tools for neglected 
disease control [18]. In some areas, neither mebendazole 
nor ivermectin are very effective against hookworm, the 
most common STH in Africa, especially when these drugs 
are used in a single dose [20,31,32]. Moreover, the rate of 
post-treatment hookworm infection is high [33], and there 
is additional evidence that the efﬁ  cacy of benzimidazole 
anthelmintics diminishes even further with frequent and 
periodic use [32]. As a result, there are justiﬁ  able concerns 
about the possibility of emerging resistance, which is now 
common for STHs that infect livestock [34]. This has 
prompted efforts to develop additional new control tools 
including anthelmintic vaccines [20,34–36]. In addition, 
the widespread use of azithromycin could promote the 
emergence of drug-resistant pneumococcus [37]. Additional 
costs must therefore be considered in order to promote 
ongoing research and development for new neglected 
diseases control tools [20].
An equally important challenge will be to determine the 
actual feasibility of integrating six different vertical control 
programmes. There are currently disparities between the 
groups targeted for lymphatic ﬁ  lariasis and onchocerciasis 
control (treatment is excluded for children under 90 cm long 
and pregnant women) and the groups targeted for STH and 
schistosome control (control is primarily aimed at school-age 
children, but the World Health Organization encourages 
treatment of pregnant women in the second and third 
trimesters). Pilot studies will be necessary to identify common 
age groups for integrated control. There are the additional 
political hurdles of persuading each of the PPPs working in 
Africa to cooperate on disease control efforts and to fully 
integrate their activities. 
November 2005  |  Volume 2  |  Issue 11  |  e336
Table 2. PPPs Engaged in Vertical Programmes for Neglected Tropical Disease Control in Africa
Programme Disease Target Major Drug(s) Used
Schistosomiasis Control Initiative Schistosomiasis and STH infections Praziquantel and albendazole
Partnership for Parasite Control STH infections Albendazole and mebendazole
Human Hookworm Vaccine Initiative Hookworm Albendazole and Vaccine Development
International Trachoma Initiative Trachoma Azithromycin
Global Alliance to Eliminate Lymphatic Filariasis Lymphatic ﬁ  lariasis Ivermectin and albendazole
African Programme for Onchocerciasis Control Onchocerciasis Ivermectin
Drugs for Neglected Disease Initiative Focus on trypanosomiasis and leishmaniasis Drug development
WHO Programme to Eliminate Sleeping Sickness Sleeping sickness Suramin and melarsoprol
DOI: 10.1371/journal.pmed.0020336.t002
DOI: 10.1371/journal.pmed.0020336.g002
Figure 2. Range of Treatment Costs Per YearPLoS Medicine  |  www.plosmedicine.org 1068
Small Costs, Huge Impact
Overall, however, the low costs for integrated neglected 
disease control represent compelling ﬁ  gures to advocate for 
a pro-poor, proactive public health intervention strategy of 
preventative chemotherapy to be delivered to all affected 
populations of Africa. Such a policy would be entirely 
compatible with the policies advocated by the Commission 
for Africa and the recently published report on the progress 
toward the MDGs submitted to the Secretary General of the 
United Nations (http:⁄⁄www.unmillenniumproject.org). The 
US$0.40 per person annual cost estimate, which would bring 
better health to several hundred million polyparasitized 
and disenfranchised poor, is a fraction of the estimated 
treatment costs for HIV/AIDS, TB, and malaria. By 
comparison, the treatment for HIV/AIDS exceeds US$200 
per year per person for the life of the individual [38], while 
TB treatment costs at least around US$200 per treatment 
in Africa [39], and the total costs of malaria treatment per 
episode are about US$7–US$10 (including indirect costs). 
It has been estimated that ﬁ  ve to ten malaria episodes per 
year can equate to a proportion of household expenditure 
of about 30%–40% in the poorest households [40]. Figure 
2 shows the range of treatment costs for a “rapid impact” 
package aimed at seven neglected diseases (schistosomiasis, 
trachoma, lymphatic ﬁ  lariasis, onchocerciasis, hookworm, 
trichuriasis, and ascariasis).
Even with their high unit costs, the current curative 
approaches to the big three diseases are “reactive” strategies. 
The treatment of individuals infected with HIV/AIDS, 
TB, and malaria fails to signiﬁ  cantly reduce transmission. 
Transmission control via bednets has a protective efﬁ  cacy 
of around 50% against malaria fevers (although a well-
documented reduction of 30%–40% in child mortality) 
[41], while condom use in Africa during the last occasional 
intercourse was reported to be 19% [42], and condom use in 
sex acts with a noncohabitating partner ranges from 13% in 
Southeast Asia to 19% in sub-Saharan Africa (p. 70 of [43]). 
In addition, ﬁ  gures published by the Joint United Nations 
Programme on HIV/AIDS show that there has been no 
increase in the prevalence of condom use during the period 
1995–2000 in three out of four countries surveyed [38,44,45]. 
Even if the targets identiﬁ  ed by the HIV/AIDS, TB, and 
malaria partnerships were to be met, transmission of all 
these infections would still continue at the present rate. 
For example if the “3 by 5” target for HIV antiretroviral 
treatments (treating 3 million people with antiretroviral 
therapy by the end of 2005) was reached, it would still leave 
90% of HIV-positive individuals infected, untreated, and 
actively transmitting HIV infection. This would effectively 
ensure an ever-increasing burden of disease. Currently, the 
burden could only be reduced by social and/or educational 
interventions, which reduce prevalence in early sexually 
active cohorts through aggressive educational campaigns 
[44,45]. While recognizing the importance of doing 
everything possible to combat the big three diseases, we urge 
decision makers, policy makers, and donors to also consider 
supporting a programme of “rapid-impact interventions,” an 
approach that would bring real beneﬁ  t to millions suffering 
disablement, poverty, and ill health. This would enable 
more equitable treatment of poor people, by providing 
such polyparasitized populations with effective and cheap 
interventions that would reduce stigma and disability, and 
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Table 3. Costs for Effective Chemotherapy Programmes against Parasitic and Infectious Debilitating and Blinding Diseases 
in Sub-Saharan Africa
Disease Target Population Numbers to Be 
Treated in Target 
Population
Drug, Source, and 
Cost If Not Donated
Delivery Strategy Distribution Costsa
(Ex Drug)
Annual Cost 
Required
Lymphatic 
ﬁ  lariasis
Total eligibleb population 
in endemic areas
300 million Mectizan donated by 
Merck and albendazole 
by GlaxoSmithKline
MDA for ﬁ  ve years $0.10 per person 
treated = $30 million
$30 million + donated 
drug
Schistosomiasis School-aged children plus 
other high risk groups
200 million Praziquantel at $0.25 per 
treatment = $50 million
MDA in high risk areas 
plus school health 
programmes 
$0.15 per person 
treated = $30 million
$30 million + $50 
million = $80 million
Intestinal 
helminths
Pre-school-aged and 
school-aged children 
400 million Albendazole at $0.02 per 
treatment = $12 million
Health days and school 
health programmes
$0.10 per person 
treated = $40 million
$40 million + $12 
million = $52 million 
Onchocerciasis Total eligibleb population 
in hyper/mezzo endemic 
areas
80 million Mectizan donated by 
Merck
MDA via community 
directed treatment
$0.10 per person 
treated = $8 million
$8 million + donated 
drug
Trachoma Total population in 
endemic areas
168 million Zithromax donated by 
Pﬁ  zer
MDA for ﬁ  ve years $0.20 per person 
treated = $34 million
$34 million + donated 
drug
Summary The population of sub-
Saharan Africa is an 
estimated 700 million
Up to 500 million 
individuals will receive 
treatment for one or 
more of these infections
$62 million + drug 
donations
$142 million $142 million + $62 
million for drugs + 
donated drugs
500 million $62 million $142 million = $204 million for ﬁ  ve 
years
Table modiﬁ  ed from [23], with permission from Elsevier. 
Assumptions for Table 3 are as follows. (1) An estimated 500 million people will be reached and treated as appropriate for ﬁ  ve diseases at a total cost of $204 million. (2) The per-person cost will therefore be approximately US$0.40 and by 
integrating treatments there could be substantial savings on delivery costs. (3) Cost saving by combining delivery could reach an estimated 25%. (4) After ﬁ  ve years’ intervention, it is expected that mass chemotherapy of some of these infections 
will no longer be necessary, but monitoring will be recommended on a longer-term basis to conﬁ  rm this hypothesis. (5) Delivery could be combined with vaccinations (polio, measles-mumps-rubella, measles) and vitamin A capsules.
aThe distribution costs are estimates derived from experience with vertical programmes. Schistosomiasis is very focal and therefore requires more extensive mapping data to determine the target population. Trachoma delivery costs include 
some allowance for surgical intervention in extreme cases.
bThe following are not eligible: children less than 90 cm in height, severely ill patients, and pregnant women.
MDA, mass drug administration.
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also reduce morbidity and mortality, thus reaching the MDGs 
quickly and cost effectively. 
Deﬁ  ning End Points for Integrated Control
Let us deﬁ  ne end points and outcomes for integrated 
control. In the case of Ascaris, Trichuris, and schistosome 
infections, the major goal is a sustainable reduction in 
worm burden and control of morbidity, while for lymphatic 
ﬁ  lariasis, onchocerciasis, and trachoma, the major goals are 
to reduce or eliminate transmission of diseases, resulting 
in much-reduced morbidity in future generations [3]. 
The externalities of these two goals are considerable and 
include improved education and economic productivity. 
The calculated loss of US$1 billion annually from lymphatic 
ﬁ  lariasis in India [46], and US$5.3 billion from blinding 
trachoma [47], and substantial reductions in future wage-
earning capacity as a result of chronic hookworm infection 
in childhood [48], illustrates the burden and costs of these 
diseases to poor individuals and communities. An added 
externality is the impact that the neglected tropical diseases 
have on the big three. Several recent papers highlight the 
immunosuppressive features of helminths (especially the 
STHs, schistosomes, and ﬁ  lariae) and their possible impact 
on promoting susceptibility to HIV/AIDS, TB, and malaria 
[49,50]. Conversely, the control of helminth infections has 
been suggested as a means to facilitate control of the big 
three [49,50], especially by reducing the frequency of malaria 
fevers, the frequency of severe and cerebral malaria, and the 
prevalence of anaemia [51–53].
We have contrasted above the unit costs of treatment for 
the neglected tropical diseases and compared them with the 
costs of HIV, TB, and malaria “control” (Figure 2). We propose 
the following model to illustrate some of these comparative 
costs for policy makers. Consider a typical sub-Saharan African 
country with a population of 10 million people, with a per-
capita government expenditure on health of US$5 and an HIV 
seroprevalence of 25%. The total annual health expenditure 
for the country would be US$50 million. If US$200 per person 
treated is used to treat the HIV-positive population, the cost 
would be US$200 × 2.5 million = US$500 million. In other 
words, ten times the available health budget is being spent on 
antiretrovirals alone. While it is expected that substantial donor 
funding (e.g., via Global Fund ﬁ  nancing) would be available 
for the purchase of antiretrovirals, there is also an expectation 
that the national health system itself would contribute to the 
ﬁ  nancing of HIV services.
Conclusions
We urge policy makers and health economists to recognize 
that although HIV, TB, and malaria are the most serious 
problems facing health planners, other diseases exist that can 
be addressed at realistic costs with effective interventions. No 
discussion of disease should use the term “control” unless 
the interventions will permanently and gradually reduce 
incidence. This will be difﬁ  cult to achieve with the big three 
due to the marginal impact of current control strategies on 
transmission—a direct contrast to what can be achieved for 
some of the “other diseases” of the MDGs affecting the poor. 
There are many people in Africa who do not have HIV 
or TB and have survived malaria, but are nonetheless 
permanently polyparasitized by debilitating, disabling, and 
sometimes fatal conditions, which can be treated at a cost of 
US$0.40 per person annually. Controlling Africa’s neglected 
diseases is one of the more convincing ways to “make poverty 
history” through affordable, pro-poor, effective, and tested 
strategies.  
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